Tang Capital Management LLC Buys New Shares in Atyr PHARMA INC (NASDAQ:ATYR)

Tang Capital Management LLC purchased a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 671,134 shares of the company's stock, valued at approximately $2,430,000. Tang Capital Management LLC owned approximately 0.80% of Atyr PHARMA at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Group One Trading LLC acquired a new stake in Atyr PHARMA during the fourth quarter worth about $26,000. Alterna Wealth Management Inc. acquired a new stake in shares of Atyr PHARMA during the 4th quarter worth approximately $36,000. Victory Capital Management Inc. purchased a new stake in shares of Atyr PHARMA during the 4th quarter valued at approximately $37,000. Raymond James Financial Inc. acquired a new position in Atyr PHARMA in the fourth quarter valued at approximately $39,000. Finally, XTX Topco Ltd acquired a new position in Atyr PHARMA in the fourth quarter valued at approximately $40,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ATYR. Leerink Partners assumed coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Monday. Finally, Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Atyr PHARMA currently has a consensus rating of "Buy" and a consensus target price of $18.60.

Atyr PHARMA Trading Down 1.2%

NASDAQ ATYR traded down $0.05 during trading on Friday, hitting $3.76. The stock had a trading volume of 484,508 shares, compared to its average volume of 929,301. The company has a market capitalization of $334.21 million, a PE ratio of -3.99 and a beta of 0.79. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average price of $3.25 and a 200 day moving average price of $3.41. Atyr PHARMA INC has a twelve month low of $1.42 and a twelve month high of $4.66.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. As a group, equities research analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.